Neurological Disorders

View All

pharma-news-for-ipsen-synox-roche-abbvie
Ipsen and Skyhawk Therapeutics Partnership; SynOx Therapeutics’ Phase III Trial; Roche’s Alecensa FDA Approval; AbbVie’s RINVOQ Phase III SELECT-GCA Trial; AskBio’s AB-1002 FDA Fast Track Designation

Ipsen Partners with Skyhawk Therapeutics for RNA-Focused Research in Rare Neurological Disorders Ipsen and Skyhawk Therapeutics have entered into an exclusive global partnership to explore and create new small molecules that can influence RNA for rare neurological conditions. Under this agreement, Ipsen has the ...

Find More

Navigating the Healthcare Horizon: Odyssey of Mergers, Funding, and Acquisitions in 2024

As we step into the crisp corridors of 2024, the healthcare landscape unfolds a compelling saga of mergers, strategic funding, and transformative acquisitions. In this month-by-month analysis, we delve into the intricate tapestry of industry dynamics, exploring the impactful maneuvers that are shaping the healthcar...

Find More

Brain-Computer Interface (BCI) in Healthcare Market
What Compelling Applications is Brain-computer Interfacing Bringing to the Healthcare Market?

Technological advancement is bringing in a new frontier in the healthcare segment with innovative tools and resourceful applications. With each passing day, it unlocks new mysteries and scales greater heights toward solving several underlying challenges. Now moving forward, how fascinating it will be if someone tel...

Find More

Digital Therapeutics in Mental Health and Neurological Disorders
Role of Digital Therapeutics (DTx) in Mental Health Management

Over the last decade, various technologies, after being evaluated rigorously, have exhibited competence in treating mental health by becoming an extension of the already present care models. Today, the patient or user can now download a clinical-grade app on the phone, tablet, or computer and use it as a reliable m...

Find More

MedTech News and Updates for GE, Vivalink, and Vektor
GE and Medtronic’s Collaboration; Vivalink’s Multi-Vital Blood Pressure Patch; Foldax’s TRIA Biopolymer Surgical Aortic Heart Valve; Vektor Medical’s vMap Clinical Validation Study; iSono’s ATUS System; Mirvie’s Test to Identify Risk of Preeclampsia

GE Healthcare and Medtronic Collaborated to Meet the Increasing Need for Outpatient Care On April 28, 2022, GE Healthcare and Medtronic entered into a collaboration to provide patients, clinicians, and payers seeking more choices of excellent care, inside and outside of the traditional hospital without compromis...

Find More

MedTech News and Updates for Bioventus, Valencia Technologies, SurGenTec Graftgun, Exactech, PathMaker Neurosystems, Boston Scientific
Bioventus’s StimRouter Pain Management Device; FDA Approval for eCoin Therapy; SurGenTec Launches ION Screw; Exactech’s Humeral Reconstruction Prosthesis; Boston Scientific’s WATCHMAN FLX LAAC Device; PathMaker Neuro’s MyoRegulator

Bioventus Receives 501(k) Clearance for StimRouter Pain Management Device On March 1, 2022, the US Food and Drug Administration (FDA) gave Bioventus' StimRouter Neuromodulation System 510(k) approval. The next-generation pain treatment device is intended to treat chronic pain caused by peripheral nerves, ex...

Find More

Mounting Prevalence of Neurological Disorders and the Key Companies Bidding to Solve the Riddle

Neurological Disorders are one of the most leading causes of injuries, death, and disability. Over more than 600 Neurological Disorders are believed to affect millions of people worldwide. These disorders have a deep impact on the patients, their families, and society at large. As per the systematic analysis for th...

Find More

Transcranial Stimulation Devices Market
The New Buzz of Transcranial Stimulation Devices in the Neurological Disorders Market

Neurological disorders are one of the major causes of death and disability across the globe. As per the figures published in The Lancet journal for the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2016, neurological disorders accounted for DALYs, which were 276 million. The mortality and morbid...

Find More